世界の医療・医薬品産業レポート

TOP  >  疾患別治験・パイプラインレポート  >  遺伝子  >  多発性嚢胞腎 - パイプラインレビュー 2017年上半期

多発性嚢胞腎 - パイプラインレビュー 2017年上半期
Polycystic Kidney Disease - Pipeline Review, H1 2017

レポートタイトル 多発性嚢胞腎 - パイプラインレビュー 2017年上半期
出版社名 Global Markets Direct
発刊日 2017-05-09
体裁 PDF / 84 ページ
シングルユーザ価格 US$ 2,000
レポート分類 疾患別治験・パイプラインレポート
地域 グローバル
領域 遺伝子
疾患名 多発性嚢胞腎
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記疾患の治療薬開発についての包括的情報、さまざまな開発ステージでの比較分析、薬剤ターゲット、作用機序(MoA)、投与方法(RoA)、分子タイプ別の薬剤評価、および最新情報、ニュースやプレスリリースなどを提供します。
また、上記疾患における治療薬開発に関わる主要企業概要、開発後期および中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycystic Kidney Disease - Overview
Polycystic Kidney Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycystic Kidney Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycystic Kidney Disease - Companies Involved in Therapeutics Development
3SBio Inc
Angion Biomedica Corp
Aptevo Therapeutics Inc
Conatus Pharmaceuticals Inc
DiscoveryBiomed Inc
Endocyte Inc
IC-MedTech Inc
Ipsen SA
Kadmon Corp LLC
ManRos Therapeutics
Metabolic Solutions Development Company LLC
Mironid Ltd
NovaTarg Therapeutics Inc
Otsuka Holdings Co Ltd
Q BioMed Inc
Regulus Therapeutics Inc
XORTX Pharma Corp
Polycystic Kidney Disease - Drug Profiles
(sodium ascorbate + menadione sodium bisulfite) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBM-43H11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DJ-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Cystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-0371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDN-8050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
menadione sodium bisulfite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSDC-0160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxypurinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGLS-4326 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PDE4 for Kidney Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STA-2842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesevatinib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNFR x TWEAKR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolvaptan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycystic Kidney Disease - Dormant Projects
Polycystic Kidney Disease - Discontinued Products
Polycystic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan
Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD
Dec 06, 2016: Regulus Announces Update on RGLS4326
Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016
Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease
Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015
May 28, 2015: Otsuka’s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease
Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide
Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease
Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease
May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease
Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development for Polycystic Kidney Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

List of Tables
Number of Products under Development for Polycystic Kidney Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Polycystic Kidney Disease - Pipeline by 3SBio Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H1 2017
Polycystic Kidney Disease - Pipeline by Aptevo Therapeutics Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Endocyte Inc, H1 2017
Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Ipsen SA, H1 2017
Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H1 2017
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H1 2017
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company LLC, H1 2017
Polycystic Kidney Disease - Pipeline by Mironid Ltd, H1 2017
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Polycystic Kidney Disease - Pipeline by Q BioMed Inc, H1 2017
Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, H1 2017
Polycystic Kidney Disease - Pipeline by XORTX Pharma Corp, H1 2017
Polycystic Kidney Disease - Dormant Projects, H1 2017
Polycystic Kidney Disease - Discontinued Products, H1 2017
Loading....